Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.07.2021 | Case report

Doxorubicin

Cardiotoxicity and heart failure: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Tron C, et al. Could pharmacogenetics testing explain anthracycline-induced cardiotoxicity sensitivity in hematologic pediatric patients? Fundamental and Clinical Pharmacology 35 (Suppl. S1): 168-169 (plus poster) abstr. PS-162, Jun 2021. Available from: URL: http://doi.org/10.1111/fcp.12670 [abstract] Tron C, et al. Could pharmacogenetics testing explain anthracycline-induced cardiotoxicity sensitivity in hematologic pediatric patients? Fundamental and Clinical Pharmacology 35 (Suppl. S1): 168-169 (plus poster) abstr. PS-162, Jun 2021. Available from: URL: http://​doi.​org/​10.​1111/​fcp.​12670 [abstract]
Metadaten
Titel
Doxorubicin
Cardiotoxicity and heart failure: 4 case reports
Publikationsdatum
01.07.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-98308-8

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Pembrolizumab

Case report

Multiple drugs

Case report

Pembrolizumab

Case report

Multiple drugs

Case report

Aspirin